Technical Analysis for LGVN - Longeveron Inc.

Grade Last Price % Change Price Change
F 5.44 -7.64% -0.45
LGVN closed down 7.64 percent on Thursday, May 6, 2021, on 9 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical LGVN trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
New 52 Week Low Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Doji - Bullish? Reversal -7.64%
Wide Bands Range Expansion -7.64%
Older End-of-Day Signals for LGVN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Longeveron Inc. Description

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.


Sector: Other
Industry: Other
Keywords: Biotechnology Life Sciences Biology Stem Cells Cell Biology Cell Therapy Mesenchymal Stem Cell Acute Respiratory Distress Syndrome

Is LGVN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 12.48
52 Week Low 5.42
Average Volume 1,005,159
200-Day Moving Average 0.00
50-Day Moving Average 6.79
20-Day Moving Average 6.30
10-Day Moving Average 6.00
Average True Range 0.50
ADX 17.23
+DI 23.05
-DI 25.45
Chandelier Exit (Long, 3 ATRs ) 7.86
Chandelier Exit (Short, 3 ATRs ) 6.93
Upper Bollinger Band 7.38
Lower Bollinger Band 5.21
Percent B (%b) 0.11
BandWidth 34.59
MACD Line -0.28
MACD Signal Line -0.24
MACD Histogram -0.0358
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.12
Resistance 3 (R3) 6.19 6.03 6.01
Resistance 2 (R2) 6.03 5.86 6.00 5.97
Resistance 1 (R1) 5.74 5.75 5.66 5.67 5.93
Pivot Point 5.58 5.58 5.54 5.54 5.58
Support 1 (S1) 5.28 5.40 5.20 5.21 4.95
Support 2 (S2) 5.12 5.30 5.09 4.91
Support 3 (S3) 4.83 5.12 4.87
Support 4 (S4) 4.76